Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan

Thrombosis and Haemostasis

Volumn 94, Issue 4, 2005, Pages 808-813

  Tanaka, Kenichi A ^c,d   Szlam, Fania ^c   Vinten Johansen, Jakob ^a   Cardin, Alan D ^b   Levy, Jerrold H ^c  

^a Carlyle Fraser Heart Center   (United States)

^b Celsus Laboratories Inc   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Antithrombin; Heparin cofactor II; Intimatan

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; HEPARIN; HEPARIN COFACTOR II; INTIMATAN; THROMBIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTICOAGULATION; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE POOR PLASMA; VOLUNTEER;

ANTICOAGULANTS; BLOOD COAGULATION; DERMATAN SULFATE; DRUG THERAPY, COMBINATION; HEPARIN; HEPARIN COFACTOR II; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBIN; THROMBOSIS;

EID: 27144514073     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-03-0197     Document Type: Article

References (25)

1. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
2. Buchanan MR, Brister SJ. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist. Thromb Res 2000; 99: 603-12.
3. Hennan JK, Hong TT, Shergill AK et al. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Thera 2002; 301: 1151-6.
4. Rand MD, Lock JB, van't Veer C et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
5. Matthai WH, Jr., Kurnik PB, Groh WC et al. Antithrombin activity during the period of percutaneous coronary revascularization: Relation to heparin use, thrombotic complications and restenosis. J Am Col Cardiol 1999;33:1248-56.
6. Tanaka KA, Szlam F, Katori N et al. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Anlag 2004; 99: 1283-9.
7. Matsuo T, Yamada T, Yamanashi T, Kodama K. Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis. Clin Lab Haematol 1989; 11: 213-9.
8. Murano G, Williams L, Miller-Andersson M, et al. Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 1980; 18: 259-62.
9. Vicente CP, He L, Pavao MS, Tollefsen DM. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood 2004; 104: 3965-70.
10. Andersson TR. Consumption of heparin cofactor II (dermatan sulfate cofactor) and antithrombin during coagulation. Thromb Res 1987;46:355-62.
11. Bertina RM, van der Linden IK, Engesser L et al. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987; 57: 196-200.
12. Kondo S, Tokunaga F, Kario K et al. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). Blood 1996; 87: 1006-12.
13. Ishiguro K, Kojima T, Kadomatsu K et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106:873-8.
14. He L, Vicente CP, Westrick RJ et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-9.
15. Andersson TR, Sie P, Pelzer H et al. Elevated levels of thrombin-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation. Thromb Res 1992; 66:591-8.
16. Duboscq C, Quintana I, Barros J, Kordich L. Heparin cofactor II in diabetic patients. Blood Coag Fibrinolysis 1994; 5: 201-4.
17. Andersson TR, Berner NS, Larsen ML et al. Plasma heparin cofactor II, protein C and antithrombin in elective surgery. Acta Chir Scand 1987; 153: 291-6.
18. Shirk RA, Parthasarathy N, San Antonio JD et al. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem 2000; 275: 18085-92.
19. Takamori N, Azuma H, Kato M et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 2004; 109: 481-6.
20. Toulon P, Jacquot C, Capron L et al. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemost 1987; 57: 263-8.
21. Toulon P, Gandrille S, Remy P et al. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome. Nephron 1992; 60: 176-80.
22. Hara T, Jojima K, Takeuchi K et al. Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis. Thromb Haemost 2004; 92: 208-10.
23. Ryan KE, Lane DA, Flynn A et al. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost 1992; 68: 563-9.
24. Taliani MR, Agnelli G, Nenci GG, Gianese F. Dermatan sulphate in patients with heparin-induced thrombocytopenia. Brit J Haematol 1999; 104: 87-9.
25. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med 2002; 126: 1394-400.